Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioFocus Enters Collaboration with Michael J. Fox Foundation

Published: Thursday, July 14, 2011
Last Updated: Thursday, July 14, 2011
Bookmark and Share
Collaboration agreement for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.

BioFocus has announced that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.

Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.

“We are delighted to have the opportunity to support The Michael J. Fox Foundation in its development of improved therapies for those living with Parkinson’s,” said Dr Kate Hilyard, VP Biological Sciences.

Dr Hilyard continued, “The collaboration will utilize BioFocus' biology platform that delivers drug discovery solutions through its experienced teams and state-of-the-art technologies”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
BioFocus Announces Agreement with ChanTest
BioFocus expands ion channel offering.
Thursday, February 07, 2013
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
BioFocus Extends Collaboration with Usher III Initiative
BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
Wednesday, June 22, 2011
BioFocus Leads Compound Library Market with Innovative Business Model
Libraries are designed to target protein families of particular interest to the subscribers.
Friday, April 15, 2011
BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays
FLT offers a robust, antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.
Monday, April 11, 2011
BioFocus Extends Collaboration with Amgen into 2012
BioFocus has announced that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services.
Friday, December 17, 2010
BioFocus Renews French Research Tax Credit Accreditation
The accreditation allows eligible French companies to benefit from significant tax relief on research carried out by BioFocus on their behalf until 2013.
Wednesday, June 09, 2010
BioFocus to Host Free Webinar on “Unleashing the Power of Computational Chemistry in Hit Finding Campaigns”
Attendees will learn how computational chemistry tools enable cost- and time-efficient HTS campaigns.
Friday, May 07, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-protein Interactions
BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, has announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, May 04, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-Protein Interactions
These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, April 13, 2010
BioFocus boosts Ion Channel Screening Capability
BioFocus has appointed Dr Iain James as Director of Biology and has commissioned an IonWorks Quattro™ high-throughput electrophysiology screening system.
Monday, September 12, 2005
BioFocus collaboration with Mitsubishi

Monday, February 24, 2003
Scientific News
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos